Nancy Gillett Net Worth

The estimated Net Worth of Nancy Gillett is at least 10.8 百万$ dollars as of 2 March 2016. Nancy Gillett owns over 822 units of Charles River Laboratories International stock worth over 2,136,072$ and over the last 21 years Nancy sold CRL stock worth over 8,700,926$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Nancy Gillett CRL stock SEC Form 4 insiders trading

Nancy has made over 30 trades of the Charles River Laboratories International stock since 2012, according to the Form 4 filled with the SEC. Most recently Nancy sold 822 units of CRL stock worth 62,324$ on 2 March 2016.

The largest trade Nancy's ever made was exercising 37,037 units of Charles River Laboratories International stock on 8 March 2013 worth over 1,406,295$. On average, Nancy trades about 4,289 units every 20 days since 2003. As of 2 March 2016 Nancy still owns at least 11,034 units of Charles River Laboratories International stock.

You can see the complete history of Nancy Gillett stock trades at the bottom of the page.

What's Nancy Gillett's mailing address?

Nancy's mailing address filed with the SEC is , , , , .

Insiders trading at Charles River Laboratories International

Over the last 22 years, insiders at Charles River Laboratories International have traded over 220,588,205$ worth of Charles River Laboratories International stock and bought 18,392 units worth 3,841,397$ . The most active insiders traders include James C Foster、Richard F Wallman、David P Johst. On average, Charles River Laboratories International executives and independent directors trade stock every 14 days with the average trade being worth of 2,223,188$. The most recent stock trade was executed by Joseph W La Plume on 8 August 2024, trading 1,780 units of CRL stock currently worth 354,861$.

What does Charles River Laboratories International do?

charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro

Complete history of Nancy Gillett stock trades at Charles River Laboratories International

Charles River Laboratories International executives and stock owners

Charles River Laboratories International executives and other stock owners filed with the SEC include:

• James Foster,
  Chairman of the Board, President, Chief Executive Officer
• David Smith,
  Chief Financial Officer, Corporate Executive Vice President
• James C. Foster,
  Chairman, CEO & Pres
• Joseph LaPlume,
  Corporate Executive Vice President, Corporate Development and Strategy
• Birgit Girshick,
  Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian
• William Barbo,
  Corporate Executive Vice President and Chief Commercial Officer
• David Ross Smith,
  Corp. Exec. VP & CFO
• William D. Barbo,
  Chief Commercial Officer & Corp. Exec. VP
• Joseph W. LaPlume,
  Corp. Exec. VP of Corp. Devel. & Strategy
• Birgit Girshick,
  Corp. Exec. VP & COO
• George Milne,
  Lead Independent Director
• George Massaro,
  Independent Director
• Robert Bertolini,
  Independent Director
• Richard Reese,
  Independent Director
• Richard Wallman,
  Independent Director
• Martin Mackay,
  Independent Director
• Deborah Kochevar,
  Independent Director
• Jean-Paul Mangeolle,
  Independent Director
• Stephen Chubb,
  Independent Director
• Virginia Wilson,
  Independent Director
• Nancy Andrews,
  Independent Director
• George Llado,
  Director
• Matthew L. Daniel,
  Corp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Todd Spencer,
  Corp. VP of Investor Relations
• Mark Mintz,
  Corp. Sr. VP & Chief Information Officer
• Prof. Julie Frearson Ph.D.,
  Corp. Sr. VP & Chief Scientific Officer
• Michael Gunnar Knell,
  Corp. Sr. VP & Chief Accounting Officer
• John J Crowley,
  SVP, Chief Accounting Officer
• Davide Molho,
  Corporate Executive VP
• Michael Gunnar Knell,
  CSVP&Chief Accounting Officer
• Craig B. Thompson,
  Director
• John W Kuo,
  CEVP General Counsel & CCO
• Victoria L Creamer,
  EVP & Chief People Officer
• David P Johst,
  Corporate Executive VP
• Jorg Geller,
  OFFICERS
• Nancy Gillett,
  Vice President
• Thomas F Ackerman,
  Sr. Vp and CFO
• Samuel O Md Thier,
  Director
• William Waltrip,
  Director
• Nancy T Chang,
  Director
• Christopher Berthoux,
  OFFICERS
• Douglas E Rogers,
  Director
• Real H Renaud,
  Executive Vice President
• Brian Bathgate,
  Corporate Vice President
• Joanne P Acford,
  Corp. Sr VP, GC and Corp. Sec
• David J Elliott,
  Officer
• Linda Mc Goldrick,
  Director
• Stephanie B Wells,
  Senior Vice President
• Cheri L Walker,
  Corporate Senior VP
• Nicholas Ventresca,
  Senior Vice President
• Michael F Ankcorn,
  Corporate Sr. Vice President
• Walter S Nimmo,
  Director
• S Louise Mccrary,
  Director
• John C Ho,
  Senior Vice President
• Alastair Stuart Mcewan,
  Corporate Vice President
• John Urquhart,
  Director
• Dennis R Shaughnessy,
  Sr. VP Corporate Development
• Robert Cawthorn,
  Director
• Flavia Pease,
  Corporate Executive VP & CFO
• Shannon M Parisotto,
  CEVP, Disc & Safety Assessment
• Reshema Kemps Polanco,
  Director